Keros Therapeutics (KROS) to Post Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($1.25) per share and revenue of $0.8070 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.07 on Monday. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55. The stock has a 50-day moving average of $10.70 and a 200-day moving average of $12.65. The firm has a market cap of $199.31 million, a PE ratio of -3.35 and a beta of 0.97.

Insider Transactions at Keros Therapeutics

In related news, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the transaction, the director owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,799.91. The trade was a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,425 shares of company stock worth $89,994. Company insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently made changes to their positions in KROS. The Manufacturers Life Insurance Company raised its holdings in shares of Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after acquiring an additional 988 shares in the last quarter. UBS Group AG lifted its stake in Keros Therapeutics by 1.1% in the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after acquiring an additional 1,091 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares in the last quarter. Creative Planning boosted its holdings in Keros Therapeutics by 9.7% in the third quarter. Creative Planning now owns 26,573 shares of the company’s stock valued at $420,000 after acquiring an additional 2,347 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in Keros Therapeutics by 5.4% during the 3rd quarter. Mackenzie Financial Corp now owns 56,768 shares of the company’s stock valued at $898,000 after purchasing an additional 2,891 shares during the period. 71.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KROS has been the topic of a number of analyst reports. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.